GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Pre-Tax Income

Nascent Biotech (Nascent Biotech) Pre-Tax Income : $-2.09 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Nascent Biotech's pretax income for the three months ended in Dec. 2023 was $-0.21 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.09 Mil. Nascent Biotech's pretax margin was %.

During the past 7 years, Nascent Biotech's highest Pretax Margin was 45.90%. The lowest was -127.87%. And the median was -47.00%.


Nascent Biotech Pre-Tax Income Historical Data

The historical data trend for Nascent Biotech's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Pre-Tax Income Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Pre-Tax Income
Get a 7-Day Free Trial -1.37 -4.00 -0.96 -0.47 -2.80

Nascent Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.84 -0.52 -0.54 -0.83 -0.21

Competitive Comparison of Nascent Biotech's Pre-Tax Income

For the Biotechnology subindustry, Nascent Biotech's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Pre-Tax Income falls into.



Nascent Biotech Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Nascent Biotech's Pretax Income for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-2.156+1.083+-1.723+0+-0.0049999999999999
=-2.80

Nascent Biotech's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.364+0.18+-0.025+0.004+2.7755575615629E-17
=-0.21

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nascent Biotech  (OTCPK:NBIO) Pre-Tax Income Explanation

Nascent Biotech's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=-0.205/0
=%

During the past 7 years, Nascent Biotech's highest Pretax Margin was 45.90%. The lowest was -127.87%. And the median was -47.00%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nascent Biotech Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech (Nascent Biotech) Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121